logo
Plus   Neg
Share
Email

Stock Alert: Tenax Surges 60% On Positive Data From Levosimendan Trial

Shares of Tenax Therapeutics, Inc. (TENX) soared over 60% on Tuesday morning after the pharma maker reported positive data from mid-stage trial of levosimendan for treatment in heart disorder.

TENX is currently trading at $2.36, up $0.91 or 62.76%, on the Nasdaq.

Tenax announced positive Phase 2 results for levosimendan to reat pulmonary hypertension and heart failure with preserved ejection fraction.

Levosimendan demonstrated a statistically significant reduction in pulmonary capillary wedge pressure, the primary efficacy analysis, compared to baseline and placebo when the measurements at rest, with legs up and on exercise were combined. Levosimendan also showed significant improvement in 6-minute walk distance compared to placebo.

While there was no significant change in pulmonary capillary wedge pressure during exercise, patients had reductions from baseline at Week 6 in pulmonary artery pressure and right atrial pressure.

Dr. Stuart Rich, Professor of Medicine at the Bluhm Cardiovascular Institute at Northwestern University commented "Levosimendan is the first drug to ever show a favorable mechanism of action with biventricular effects in patients with PH-HFpEF. The consistency of the hemodynamic data and improvement in 6-minute walk demonstrates that levosimendan has great promise as a treatment for PH-HFpEF which has a serious unmet need. The favorable safety profile, especially the absence of any proarrhythmic effects, supports the further development with a phase 3 trial."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
U.S. Court grants Tiffany's motion to expedite lawsuit against LVMH Moët Hennessy-Louis Vuitton. However, the court has not agreed to Tiffany request for trial before November 24. Biotech company Illumina agreed to buy healthcare company GRAIL, Inc. in a cash and stock deal valued at $8 billion. This includes $3.5 billion in cash and $4.5 billion in shares of Illumina common stock. GRAIL focuses on multi-cancer early detection from blood. It is in the process of developing the technology and providing clinical data required to launch the Galleri multi-cancer screening test. Oracle and Walmart have tentatively agreed to acquire 20% of the newly formed TikTok Global business, the companies said in a statement.
Follow RTT